Skip to main content

Table 1 Association between infiltrating immune cell counts (IICCs) in women biopsied for benign breast disease and risk of subsequent invasive breast cancer risk

From: Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer

  IICCs in normal tissue (%) IICCs in BBD lesion (%)
Per 5% increase < 5 ≥ 5 Missing Per 5% increase < 5 ≥ 5 Missing
Overall
 Cases/controls   424/422 84/81 11/17   326/335 93/82 100/103
 Age-adjusted OR 1.05 (0.96–1.15) 1.00 1.04 (0.74–1.45) 1.04 (0.94–1.16) 1.00 1.16 (0.83–1.62)
 Multivariable-adjusted ORa 1.05 (0.96–1.16) 1.00 1.04 (0.74–1.48) 1.06 (0.96–1.18) 1.00 1.11 (0.79–1.58)
Menopausal status
Premenopausal
  Cases/controls   165/142 41/38 3/7   131/122 42/23 36/42
  Age-adjusted OR 1.02 (0.91–1.13) 1.00 0.95 (0.58–1.56) 1.17 (0.97–1.41) 1.00 1.73 (0.98–3.05)
  Multivariable-adjusted OR 1.01 (0.90–1.14) 1.00 0.95 (0.56–1.63) 1.16 (0.96–1.40) 1.00 1.52 (0.83–2.79)
Postmenopausal
  Cases/controls   178/206 32/29 4/9   132/156 37/46 45/42
  Age-adjusted OR 1.37 (1.01–1.85) 1.00 1.28 (0.75–2.21) 0.96 (0.82–1.13) 1.00 0.94 (0.57–1.54)
  Multivariable-adjusted OR 1.34 (0.99–1.83) 1.00 1.19 (0.67–2.09) 0.99 (0.83–1.19) 1.00 0.98 (0.58–1.66)
P for heterogeneityb   0.56    0.23  
BBD
  Non-proliferative
  Cases/controls   59/78 11/17 2/4   27/46 8/10 37/43
  Age-adjusted OR 1.03 (0.85–1.25) 1.00 1.00 (0.98–1.01) 1.07 (0.79–1.44) 1.00 1.40 (0.40–4.00)
  Multivariable-adjusted ORc 1.12 (0.90–1.39) 1.00 1.15 (0.45–2.95) 1.15 (0.69–1.91) 1.00 1.43 (0.42–4.82)
Proliferative
  Cases/controls   356/329 68/62 9/12   298/284 85/71 50/48
  Age-adjusted OR 1.06 (0.95–1.17) 1.00 1.00 (0.99–1.01) 1.05 (0.94–1.18) 1.00 1.15 (0.80–1.63)
  Multivariable-adjusted OR 1.03 (0.93–1.15) 1.00 0.94 (0.64–1.39) 1.06 (0.95–1.19) 1.00 1.07 (0.74–1.55)
P for heterogeneityb   0.88    0.83  
BMI
18.5–24.9 kg/m2
  Cases/controls   170/166 36/31 2/6   128/119 41/34 39/50
  Age-adjusted OR 1.02 (0.87–1.19) 1.00 1.10 (0.65–1.88) 1.03 (0.88–1.22) 1.00 1.13 (0.67–1.90)
  Multivariable-adjusted OR 1.10 (0.93–1.30) 1.00 1.23 (0.70–2.16) 1.10 (0.92–1.33) 1.00 1.18 (0.67–2.07)
≥ 25.0 kg/m2
  Cases/controls   208/210 37/38 7/6   165/166 35/45 52/43
  Age-adjusted OR 1.05 (0.92–1.20) 1.00 1.02 (0.62–1.68) 0.95 (0.83–1.10) 1.00 0.74 (0.67–1.22)
  Multivariable-adjusted OR 1.00 (0.88–1.15) 1.00 0.91 (0.54–1.53) 1.00 (0.86–1.17) 1.00 0.68 (0.40–1.14)
P for heterogeneityb   0.45    0.23  
Cigarette smoking
No
  Cases/controls   149/171 35/31 3/4   113/128 34/32 40/46
  Age-adjusted OR 1.03 (0.85–1.25) 1.00 1.40 (0.82–2.40) 0.95 (0.78–1.14) 1.00 1.15 (0.66–1.99)
  Multivariable-adjusted OR 1.12 (0.90–1.39) 1.00 1.49 (0.85–2.61) 0.92 (0.76–1.13) 1.00 1.09 (0.61–1.97)
Yes
  Cases/controls   173/185 25/32 5/5   139/155 32/30 32/37
  Age-adjusted OR 1.06 (0.95–1.17) 1.00 0.82 (0.47–1.45) 1.06 (0.92–1.22) 1.00 1.20 (0.69–2.08)
  Multivariable-adjusted OR 1.03 (0.93–1.15) 1.00 0.73 (0.40–1.35) 1.13 (0.97–1.32) 1.00 1.29 (0.72–2.32)
P for heterogeneityb   0.12    0.86  
  1. aAdjusted for age at enrollment, BMI, menopausal status, hormonal therapy use ever, family history of breast cancer, smoking ever, pack-years of smoking, age at menarche, age at first birth/parity, and benign breast disease histology unless included as the main exposure
  2. bValues were derived from multivariable models with the categorical exposures